Celcuity Inc. filings document formal disclosures for a clinical-stage biotechnology company developing targeted oncology therapies. Recent 8-K reports cover gedatolisib and VIKTORIA-1 clinical-trial results in HR+/HER2- advanced breast cancer, FDA-related regulatory updates, financial results, Regulation FD materials, and amendments to a loan and security agreement.
Proxy materials describe annual meeting matters, director elections, auditor ratification, executive compensation votes, stock incentive plans, and employee stock purchase plan amendments. Governance filings also record board composition changes and director compensation arrangements.
Celcuity Inc. (CELC) filed an 8-K detailing several capital-raising and financing actions dated 28 Jul 2025.
Loan amendment: The company executed a Second Amendment to its Amended & Restated Loan and Security Agreement with Innovatus and Oxford Finance. Key changes: (i) allows issuance of $150 m aggregate principal Convertible Senior Notes due 2031 and related capped-call transactions; (ii) permits equity conversion of the notes solely into common shares (cash only for fractional shares); (iii) requires a one-time $25 k amendment fee paid to Oxford; and (iv) extends to 9 May 2026 Innovatus’ option to convert up to 20 % of Term A principal into CELC stock at $10.00 per share.
Capital markets activity: Celcuity launched a concurrent offering for $150 m of the Notes plus $75 m of common stock. Proceeds would strengthen liquidity and fund operations.
Additional debt capacity: Management believes the Phase 3 VIKTORIA-1 data achieve the “Term D Milestone,” enabling a $30 m Term D Loan draw by 31 Aug 2025.
Preliminary cash position: Cash, equivalents and short-term investments are expected at ~<$168.4 m> on 30 Jun 2025 versus $283.1 m a year earlier (-41 %). Figures are unaudited and subject to change.
Forward-looking statements caution that the offerings may not close, the Term D draw might not occur, and final June-quarter financials could differ.
Celcuity Inc. (CELC) filed a Form 144 indicating an intention to sell up to 100,000 common shares through RBC Capital Markets on or about 28 Jul 2025. At the filing’s reference price, the shares have an aggregate market value of $4.398 million and represent roughly 0.3 % of the 37.87 million shares outstanding.
The shares were originally acquired on 28 Feb 2014 via an investment transaction paid by check. The filer reports no sales of Celcuity securities in the past three months. The notice states that the seller is unaware of any undisclosed material adverse information and affirms compliance with Rule 10b5-1 if applicable. The planned sale will take place on the NASDAQ exchange. No additional financial data, earnings information, or prior insider transactions are disclosed in this filing.
Celcuity Inc. (CELC) filed a Form 144 indicating an intention to sell up to 100,000 common shares through RBC Capital Markets on or about 28 Jul 2025. At the filing’s reference price, the shares have an aggregate market value of $4.398 million and represent roughly 0.3 % of the 37.87 million shares outstanding.
The shares were originally acquired on 28 Feb 2014 via an investment transaction paid by check. The filer reports no sales of Celcuity securities in the past three months. The notice states that the seller is unaware of any undisclosed material adverse information and affirms compliance with Rule 10b5-1 if applicable. The planned sale will take place on the NASDAQ exchange. No additional financial data, earnings information, or prior insider transactions are disclosed in this filing.
Celcuity Inc. (NASDAQ: CELC) filed a Form 144 indicating the intent to sell 9,325 common shares, valued at roughly $420,766 based on the market price when the form was prepared. The shares, which equal about 0.02 % of the 37.9 million shares outstanding, were acquired through two stock-grant awards on 05/14/2022 (7,843 sh) and 05/12/2021 (1,482 sh). No cash consideration was paid for the grants.
The proposed sale is expected on or after 07/28/2025 through broker RBC Capital Markets, with execution on the NASDAQ market. The filer reported no other sales during the past three months and affirmed they possess no undisclosed material adverse information about the company. Form 144 is a notice only; execution is not guaranteed and volume limits under Rule 144 apply.
Given the modest size relative to CELC’s float and the routine nature of insider liquidity events, the filing is unlikely to be material for investors unless accompanied by additional insider activity or negative corporate developments.
Celcuity Inc. (NASDAQ: CELC) filed a Form 144 indicating the intent to sell 9,325 common shares, valued at roughly $420,766 based on the market price when the form was prepared. The shares, which equal about 0.02 % of the 37.9 million shares outstanding, were acquired through two stock-grant awards on 05/14/2022 (7,843 sh) and 05/12/2021 (1,482 sh). No cash consideration was paid for the grants.
The proposed sale is expected on or after 07/28/2025 through broker RBC Capital Markets, with execution on the NASDAQ market. The filer reported no other sales during the past three months and affirmed they possess no undisclosed material adverse information about the company. Form 144 is a notice only; execution is not guaranteed and volume limits under Rule 144 apply.
Given the modest size relative to CELC’s float and the routine nature of insider liquidity events, the filing is unlikely to be material for investors unless accompanied by additional insider activity or negative corporate developments.
Celcuity’s Form 8-K furnishes topline data from the PIK3CA wild-type cohort of its Phase 3 VIKTORIA-1 trial in HR-positive/HER2-negative metastatic breast cancer. Adding gedatolisib to fulvestrant plus palbociclib cut risk of progression or death by 76 % (HR 0.24; p<0.0001) and extended blinded-review median PFS to 9.3 months vs. 2.0 months. The gedatolisib+fulvestrant doublet reduced risk by 67 % (HR 0.33) with mPFS of 7.4 months. Both hazard ratios and incremental PFS gains are the best reported for second-line HR+/HER2- ABC in any Phase 3 study. Discontinuations and class-related AEs (hyperglycemia, stomatitis) were lower than prior Phase 1b data and other approved regimens, indicating an improved tolerability profile.
Celcuity plans to file a New Drug Application with the FDA in Q4 2025; full data will be presented at a medical meeting in 2025. Topline results from the separate PIK3CA-mutant cohort are expected by year-end 2025.
Celcuity’s Form 8-K furnishes topline data from the PIK3CA wild-type cohort of its Phase 3 VIKTORIA-1 trial in HR-positive/HER2-negative metastatic breast cancer. Adding gedatolisib to fulvestrant plus palbociclib cut risk of progression or death by 76 % (HR 0.24; p<0.0001) and extended blinded-review median PFS to 9.3 months vs. 2.0 months. The gedatolisib+fulvestrant doublet reduced risk by 67 % (HR 0.33) with mPFS of 7.4 months. Both hazard ratios and incremental PFS gains are the best reported for second-line HR+/HER2- ABC in any Phase 3 study. Discontinuations and class-related AEs (hyperglycemia, stomatitis) were lower than prior Phase 1b data and other approved regimens, indicating an improved tolerability profile.
Celcuity plans to file a New Drug Application with the FDA in Q4 2025; full data will be presented at a medical meeting in 2025. Topline results from the separate PIK3CA-mutant cohort are expected by year-end 2025.